Inlyta

Chemical Nameaxitinib
Dosage FormTablet (oral; 1 mg, 5 mg)
Drug ClassKinase inhibitors
SystemUrinary
CompanyPfizer
Approval Year2012

Indication

  • Indicated in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
  • Indicated in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC
  • Indicated as a single agent, for the treatment of advanced RCC after failure of one prior systemic therapy
Last updated on 4/25/2022

More on this drug: Clinical Trials

Document TitleYearSource
Inlyta (axitinib) Prescribing Information.2012Pfizer Inc., New York, NY
Document TitleYearSource
Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2022The Journal of Urology
Second line treatments for advanced hepatocellular carcinoma: a systematic review and Bayesian network meta analysis. 2022Clinical and Experimental Medicine
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2022European Association of Urology
Systemic therapy for metastatic renal cell carcinoma in the first‑line setting: a systematic review and network meta‑analysis.2021Cancer Immunology, Immunotherapy
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma. 2021European Association of Urology
Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: a systematic review and meta-analysis. 2021European Journal of Cancer
Targeted therapy for metastatic renal cell carcinoma. 2020Cochrane Database of Systematic Reviews
What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.2020BMJ Open
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.2020Therapeutic Advances in Medical Oncology
Comparative efficacy of first-line immune-based combination therapies in metastatic renal cell carcinoma: a systematic review and network meta-analysis.2020Cancers
The clinical significance of routine risk categorization in metastatic renal cell carcinoma and its impact on treatment decision-making: a systematic review.2020Future Oncology
First-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis.2019European Urology
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis.2019EBioMedicine
Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.2019BMJ Open
First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. 2018European Urology
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.2017PLoS One
Comparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysis.2016OncoTargets and Therapy
Document TitleYearSource
EAU guidelines on renal cell carcinoma.2022European Association of Urology
Kidney cancer, version 3.2022. 2022Journal of the National Comprehensive Cancer Network
Kidney cancer, version 1.2021.2020Journal of the National Comprehensive Cancer Network

Have we missed a study, or would you like to comment on a study?